{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:01:20Z","timestamp":1791925280229,"version":"4.3.4"},"reference-count":63,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008665","name":"University of Luxembourg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008665","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Phenothiazines (PTZ) were developed as inhibitors of monoamine neurotransmitter receptors, notably dopamine receptors. Because of this activity they have been used for decades as antipsychotic drugs. In addition, they possess significant anti-cancer properties and several attempts for their repurposing were made. However, their incompletely understood polypharmacology is challenging. Here we examined the potential of the PTZ fluphenazine (Flu) and its mustard derivative (Flu-M) to synergistically act on two cancer associated targets, calmodulin (CaM) and the tumor suppressor protein phosphatase 2A (PP2A). Both proteins are known to modulate the Ras- and MAPK-pathway, cell viability and features of cancer cell stemness. Consistently, we show that the combination of a CaM inhibitor and the PP2A activator DT-061 synergistically inhibited the 3D-spheroid formation of MDA-MB-231 (K-Ras-G13D), NCI-H358 (K-Ras-G12C) and A375 (B-raf-V600E) cancer cells, and increased apoptosis in MDA-MB-231. We reasoned that these activities remain combined in PTZ, which were the starting point for PP2A activator development, while several PTZ are known CaM inhibitors. We show that both Flu and Flu-M retained CaM inhibitory activity in vitro and in cells, with a higher potency of the mustard derivative in cells. In line with the CaM dependence of Ras plasma membrane organization, the mustard derivative potently reduced the functional membrane organization of oncogenic Ras, while DT-061 had a negligible effect. Like DT-061, both PTZ potently decreased c-MYC levels, a hallmark of PP2A activation. Benchmarking against the KRAS-G12C specific inhibitor AMG-510 in MIA PaCa-2 cells revealed a higher potency of Flu-M than combinations of DT-061 and a CaM inhibitor on MAPK-output and a strong effect on cell proliferation. While our study is limited, our results suggest that improved PTZ derivatives that retain both, their CaM inhibitory and PP2A activating properties, but have lost their neurological side-effects, may be interesting to pursue further as anti-cancer agents.<\/jats:p>","DOI":"10.1371\/journal.pone.0268635","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T17:40:50Z","timestamp":1653586850000},"page":"e0268635","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Potential of phenothiazines to synergistically block calmodulin and reactivate PP2A in cancer cells"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7305-9845","authenticated-orcid":true,"given":"Ganesh Babu","family":"Manoharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunday","family":"Okutachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2769-0745","authenticated-orcid":true,"given":"Daniel","family":"Abankwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"issue":"1","key":"pone.0268635.ref001","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S1734-1140(12)70726-0","article-title":"Chemical structure of phenothiazines and their biological activity","volume":"64","author":"A Jaszczyszyn","year":"2012","journal-title":"Pharmacol Rep"},{"issue":"3","key":"pone.0268635.ref002","first-page":"509","article-title":"Inhibition of calmodulin by phenothiazines and related drugs: structure-activity relationships","volume":"222","author":"WC Prozialeck","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"pone.0268635.ref003","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbamcr.2013.10.021","article-title":"The many faces of calmodulin in cell proliferation, programmed cell death, autophagy, and cancer","volume":"1843","author":"MW Berchtold","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"pone.0268635.ref004","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ceca.2018.09.002","article-title":"Calmodulin-binding proteins: A journey of 40 years","volume":"75","author":"RK Sharma","year":"2018","journal-title":"Cell Calcium"},{"issue":"6","key":"pone.0268635.ref005","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.1986.4.6.994","article-title":"Calmodulin: a potential target for cancer chemotherapeutic agents","volume":"4","author":"WN Hait","year":"1986","journal-title":"J Clin Oncol"},{"issue":"20","key":"pone.0268635.ref006","first-page":"6636","article-title":"The effect of calmodulin inhibitors with bleomycin on the treatment of patients with high grade gliomas","volume":"50","author":"WN Hait","year":"1990","journal-title":"Cancer Res"},{"issue":"3","key":"pone.0268635.ref007","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1104\/pp.118.3.965","article-title":"Identification of the binding and inhibition sites in the calmodulin molecule for ophiobolin A by site-directed mutagenesis","volume":"118","author":"T Kong Au","year":"1998","journal-title":"Plant Physiol"},{"issue":"5","key":"pone.0268635.ref008","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0021-9258(18)61599-6","article-title":"Calmodulin is labeled at lysine 148 by a chemically reactive phenothiazine","volume":"262","author":"FM Faust","year":"1987","journal-title":"J Biol Chem"},{"issue":"4","key":"pone.0268635.ref009","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"J Singh","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"pone.0268635.ref010","first-page":"404","article-title":"Pharmacological properties of fluphenazine-mustard, an irreversible calmodulin antagonist","volume":"32","author":"WN Hait","year":"1987","journal-title":"Mol Pharmacol"},{"key":"pone.0268635.ref011","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ejmech.2018.04.001","article-title":"Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives","volume":"151","author":"RK Singh","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"7477","key":"pone.0268635.ref012","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"JM Ostrem","year":"2013","journal-title":"Nature"},{"issue":"3","key":"pone.0268635.ref013","article-title":"Targeting KRAS Mutant Cancers with a Covalent G12","volume":"172","author":"MR Janes","year":"2018","journal-title":"C-Specific Inhibitor. Cell"},{"issue":"7781","key":"pone.0268635.ref014","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"J Canon","year":"2019","journal-title":"Nature"},{"issue":"1","key":"pone.0268635.ref015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients","volume":"10","author":"J Hallin","year":"2020","journal-title":"Cancer Discovery"},{"issue":"13","key":"pone.0268635.ref016","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors","volume":"383","author":"DS Hong","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0268635.ref017","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nchembio.1560","article-title":"Small-molecule modulation of Ras signaling","volume":"10","author":"J Spiegel","year":"2014","journal-title":"Nat Chem Biol"},{"issue":"8","key":"pone.0268635.ref018","article-title":"A Non-Canonical Calmodulin Target Motif Comprising a Polybasic Region and Lipidated Terminal Residue Regulates Localization","volume":"21","author":"BMM Grant","year":"2020","journal-title":"IJMS"},{"issue":"1","key":"pone.0268635.ref019","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1042\/BST20200964","article-title":"Promotion of cancer cell stemness by Ras","volume":"49","author":"R Chippalkatti","year":"2021","journal-title":"Biochem Soc Trans"},{"issue":"5","key":"pone.0268635.ref020","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.cell.2015.10.041","article-title":"K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling","volume":"163","author":"MT Wang","year":"2015","journal-title":"Cell"},{"issue":"40","key":"pone.0268635.ref021","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.1038\/onc.2016.59","article-title":"Cancer stem cell drugs target K-ras signaling in a stemness context","volume":"35","author":"AK Najumudeen","year":"2016","journal-title":"Oncogene"},{"key":"pone.0268635.ref022","article-title":"A covalent calmodulin inhibitor as a tool to study cellular mechanisms of K-Ras-driven stemness","author":"S Okutachi","year":"2021","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"pone.0268635.ref023","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ab.2019.02.015","article-title":"High-throughput amenable fluorescence-assays to screen for calmodulin-inhibitors","volume":"572","author":"GB Manoharan","year":"2019","journal-title":"Anal Biochem"},{"issue":"6","key":"pone.0268635.ref024","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/S1470-2045(12)70558-2","article-title":"Protein phosphatase 2A: a target for anticancer therapy","volume":"14","author":"D Perrotti","year":"2013","journal-title":"Lancet Oncol"},{"issue":"6","key":"pone.0268635.ref025","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/febs.13573","article-title":"All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase","volume":"283","author":"J Sangodkar","year":"2016","journal-title":"FEBS J"},{"issue":"2","key":"pone.0268635.ref026","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ccr.2004.07.009","article-title":"Species- and cell type-specific requirements for cellular transformation","volume":"6","author":"A Rangarajan","year":"2004","journal-title":"Cancer Cell"},{"issue":"3","key":"pone.0268635.ref027","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.cell.2009.10.006","article-title":"Serine\/threonine phosphatases: mechanism through structure","volume":"139","author":"Y. Shi","year":"2009","journal-title":"Cell"},{"key":"pone.0268635.ref028","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/bs.acr.2019.03.009","article-title":"PP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer","volume":"144","author":"H Fowle","year":"2019","journal-title":"Adv Cancer Res"},{"issue":"7","key":"pone.0268635.ref029","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1593\/neo.12768","article-title":"Circumventing cellular control of PP2A by methylation promotes transformation in an Akt-dependent manner","volume":"14","author":"JB Jackson","year":"2012","journal-title":"Neoplasia"},{"issue":"1","key":"pone.0268635.ref030","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cell.2007.04.044","article-title":"CIP2A inhibits PP2A in human malignancies","volume":"130","author":"MR Junttila","year":"2007","journal-title":"Cell"},{"issue":"3","key":"pone.0268635.ref031","doi-asserted-by":"crossref","first-page":"437","DOI":"10.15252\/embr.201642788","article-title":"Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A\/B56","volume":"18","author":"J Wang","year":"2017","journal-title":"EMBO Rep"},{"issue":"1","key":"pone.0268635.ref032","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1158\/0008-5472.CAN-16-1267-T","article-title":"PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis","volume":"77","author":"X Zhou","year":"2017","journal-title":"Cancer Res"},{"issue":"450","key":"pone.0268635.ref033","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaq1093","article-title":"PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells","volume":"10","author":"O Kauko","year":"2018","journal-title":"Sci Transl Med"},{"issue":"6","key":"pone.0268635.ref034","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1172\/JCI89548","article-title":"Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth","volume":"127","author":"J Sangodkar","year":"2017","journal-title":"J Clin Invest"},{"issue":"19","key":"pone.0268635.ref035","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1016\/j.bmc.2015.07.007","article-title":"Reengineered tricyclic anti-cancer agents","volume":"23","author":"DB Kastrinsky","year":"2015","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"pone.0268635.ref036","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.03.038","article-title":"Selective PP2A Enhancement through Biased Heterotrimer Stabilization","volume":"181","author":"D Leonard","year":"2020","journal-title":"Cell"},{"issue":"3","key":"pone.0268635.ref037","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.cell.2020.03.051","article-title":"Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2","volume":"181","author":"K Morita","year":"2020","journal-title":"Cell"},{"key":"pone.0268635.ref038","doi-asserted-by":"crossref","first-page":"27540","DOI":"10.1038\/srep27540","article-title":"Pharmacological exploitation of the phenothiazine antipsychotics to develop novel antitumor agents-A drug repurposing strategy","volume":"6","author":"CH Wu","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"pone.0268635.ref039","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/1389450003349191","article-title":"Antitumor potential and possible targets of phenothiazine-related compounds","volume":"1","author":"N Motohashi","year":"2000","journal-title":"Curr Drug Targets"},{"issue":"3","key":"pone.0268635.ref040","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.07.005","article-title":"Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening","volume":"170","author":"ER McDonald","year":"2017","journal-title":"Cell"},{"issue":"W1","key":"pone.0268635.ref041","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies","volume":"48","author":"A Ianevski","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"pone.0268635.ref042","article-title":"The toxicity of poisons applied jointly","author":"CI Bliss","year":"1939","journal-title":"Annals of Applied Biology"},{"key":"pone.0268635.ref043","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies","volume":"4","author":"B Yadav","year":"2014","journal-title":"Sci Rep"},{"issue":"11","key":"pone.0268635.ref044","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1093\/bioinformatics\/btaa138","article-title":"Breeze: an integrated quality control and data analysis application for high-throughput drug screening","volume":"36","author":"S Potdar","year":"2020","journal-title":"Bioinformatics"},{"key":"pone.0268635.ref045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ab.2017.05.017","article-title":"Binding assay for characterization of protein kinase inhibitors possessing sub-picomolar to sub-millimolar affinity","volume":"531","author":"H Sinijarv","year":"2017","journal-title":"Anal Biochem"},{"issue":"2","key":"pone.0268635.ref046","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/bit.1179","article-title":"Transient gene expression: recombinant protein production with suspension-adapted HEK293-EBNA cells","volume":"75","author":"P Meissner","year":"2001","journal-title":"Biotechnol Bioeng"},{"issue":"4","key":"pone.0268635.ref047","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.125693","article-title":"Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma","volume":"4","author":"R Tohme","year":"2019","journal-title":"JCI Insight"},{"issue":"625","key":"pone.0268635.ref048","article-title":"Calmodulin disrupts plasma membrane localization of farnesylated KRAS4b by sequestering its lipid moiety","volume":"13","author":"BMM Grant","year":"2020","journal-title":"Science Signaling"},{"issue":"7","key":"pone.0268635.ref049","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.chembiol.2012.05.019","article-title":"Design and application of in vivo FRET biosensors to identify protein prenylation and nanoclustering inhibitors","volume":"19","author":"M Kohnke","year":"2012","journal-title":"Chem Biol"},{"issue":"6","key":"pone.0268635.ref050","doi-asserted-by":"crossref","first-page":"e66425","DOI":"10.1371\/journal.pone.0066425","article-title":"Cellular FRET-Biosensors to Detect Membrane Targeting Inhibitors of N-Myristoylated Proteins","volume":"8","author":"AK Najumudeen","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"pone.0268635.ref051","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1128\/MCB.26.7.2832-2844.2006","article-title":"Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation","volume":"26","author":"HK Arnold","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"3","key":"pone.0268635.ref052","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0021-9258(17)49933-9","article-title":"Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers","volume":"295","author":"CC Farrington","year":"2020","journal-title":"J Biol Chem"},{"issue":"2","key":"pone.0268635.ref053","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1172\/JCI65093","article-title":"Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia","volume":"124","author":"A Gutierrez","year":"2014","journal-title":"J Clin Invest"},{"key":"pone.0268635.ref054","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.biopha.2017.11.012","article-title":"Psychotropic agent thioridazine elicits potent in vitro and in vivo anti-melanoma effects","volume":"97","author":"X Jiang","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"1\u20133","key":"pone.0268635.ref055","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejphar.2010.08.045","article-title":"Multiple non-psychiatric effects of phenothiazines: a review","volume":"648","author":"G Sudeshna","year":"2010","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"pone.0268635.ref056","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2174\/138945006778226624","article-title":"Cytotoxic potential of phenothiazines","volume":"7","author":"N Motohashi","year":"2006","journal-title":"Curr Drug Targets"},{"issue":"9","key":"pone.0268635.ref057","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1007\/s00268-006-0035-3","article-title":"DRD2\/DARPP-32 expression correlates with lymph node metastasis and tumor progression in patients with esophageal squamous cell carcinoma","volume":"30","author":"L Li","year":"2006","journal-title":"World J Surg"},{"issue":"4","key":"pone.0268635.ref058","doi-asserted-by":"crossref","first-page":"882","DOI":"10.18632\/oncotarget.1801","article-title":"Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma","volume":"5","author":"J Li","year":"2014","journal-title":"Oncotarget"},{"issue":"1","key":"pone.0268635.ref059","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.molonc.2014.08.008","article-title":"Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells","volume":"9","author":"LH Hoeppner","year":"2015","journal-title":"Mol Oncol"},{"issue":"23","key":"pone.0268635.ref060","doi-asserted-by":"crossref","first-page":"10339","DOI":"10.7314\/APJCP.2014.15.23.10339","article-title":"Dopamine receptor gene (DRD1-DRD5) expression changes as stress factors associated with breast cancer","volume":"15","author":"M Pornour","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"pone.0268635.ref061","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1124\/jpet.119.256818","article-title":"Cancer and the Dopamine D2 Receptor: A Pharmacological Perspective","volume":"370","author":"JS Weissenrieder","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"pone.0268635.ref062","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2013-03-492181","article-title":"Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies","volume":"122","author":"JJ Oaks","year":"2013","journal-title":"Blood"},{"key":"pone.0268635.ref063","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2019.10.007","article-title":"A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity","volume":"468","author":"C Vicente","year":"2020","journal-title":"Cancer Lett"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0268635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T17:41:49Z","timestamp":1653586909000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0268635"}},"subtitle":[],"editor":[{"given":"Irina V.","family":"Balalaeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":63,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0268635","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]}}}